Featured Publications
Illusory generalizability of clinical prediction models
Chekroud A, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett P, Koutsouleris N, Krumholz H, Krystal J, Paulus M. Illusory generalizability of clinical prediction models. Science 2024, 383: 164-167. PMID: 38207039, DOI: 10.1126/science.adg8538.Peer-Reviewed Original ResearchLongitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study
Simon P, Jiang Y, Buta E, Sartor CE, Krishnan-Sarin S, Gueorguieva R. Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study. JAMA Network Open 2022, 5: e223549. PMID: 35319763, PMCID: PMC8943628, DOI: 10.1001/jamanetworkopen.2022.3549.Peer-Reviewed Original ResearchConceptsNicotine product useCigar useTobacco usersTobacco useHealth StudyCigarette useProduct useWave 1Significant public health concernLongitudinal trajectoriesPublic health concernNon-Hispanic whitesTobacco product useLogistic regression modelsTobacco use behaviorsComplex survey designMultinomial logistic regression modelsDays of useSocioecological factorsMAIN OUTCOMESmokeless tobaccoLower oddsNicotine productsLatent class growth analysisSociodemographic factorsTrajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Gueorguieva R, Chekroud AM, Krystal JH. Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry 2017, 4: 230-237. PMID: 28189575, PMCID: PMC5340978, DOI: 10.1016/s2215-0366(17)30038-x.Peer-Reviewed Original ResearchConceptsActive medicationActive treatmentClinical trialsDepression severityHamilton Depression Rating Scale scoresDepression Rating Scale scoresClinical Global Impression scoresIndividual patient-level dataDouble-blind treatmentPlacebo-controlled trialPatterns of relapseGlobal Impression scoresIndividual patient dataPrevention of relapseTrajectory class membershipTreatment of depressionMajor depressive disorderRating Scale scoresPatient-level dataPost-traumatic stress disorderTreatment discontinuationAntidepressant treatmentClinical responseAlcohol Research CenterAntidepressant medicationTemporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking daysJoint analysis of repeatedly observed continuous and ordinal measures of disease severity
Gueorguieva RV, Sanacora G. Joint analysis of repeatedly observed continuous and ordinal measures of disease severity. Statistics In Medicine 2006, 25: 1307-1322. PMID: 16217846, DOI: 10.1002/sim.2270.Peer-Reviewed Original ResearchMove Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry
Gueorguieva R, Krystal JH. Move Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry. JAMA Psychiatry 2004, 61: 310-317. PMID: 14993119, DOI: 10.1001/archpsyc.61.3.310.Peer-Reviewed Original ResearchCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016, 3: 243-250. PMID: 26803397, DOI: 10.1016/s2215-0366(15)00471-x.Peer-Reviewed Original ResearchConceptsTreatment outcomesTreatment groupsEscitalopram treatment groupSpecific antidepressantsPatient-reported dataSequenced Treatment AlternativesClinical trial dataIndependent clinical trialsClinical remissionSymptomatic remissionClinical trialsTreatment efficacyPatientsProspective identificationTreatment alternativesTrial dataDepressionRemissionAntidepressantsOutcomesGroupLevel 1CitalopramCohortClinicians
2024
Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial
Horvath M, Pittman B, O’Malley S, Grutman A, Khan N, Gueorguieva R, Brewer J, Garrison K. Smartband-based smoking detection and real-time brief mindfulness intervention: findings from a feasibility clinical trial. Annals Of Medicine 2024, 56: 2352803. PMID: 38823419, PMCID: PMC11146247, DOI: 10.1080/07853890.2024.2352803.Peer-Reviewed Original ResearchConceptsBrief mindfulness interventionsMindfulness exercisesTreatment startersMindfulness interventionSmoking interventionsOnline mindfulness trainingWhite non-HispanicMindfulness trainingTreatment fidelityFeasibility measuresHelpfulness ratingsNon-HispanicDaily smokersPredicting smokingReduce smokingExerciseSmokingCigarette smokingInterventionLow completenessAdherenceParticipantsSmartbandAcceptanceMindfulnessA randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol
Bold K, Sharma A, Haeny A, Gueorguieva R, Buta E, Baldassarri S, Lempert L, Krishnan-Sarin S, O’Malley S. A randomized controlled trial of potential tobacco policies prohibiting menthol flavor in cigarettes and e-cigarettes: a study protocol. BMC Psychiatry 2024, 24: 201. PMID: 38475757, PMCID: PMC10935798, DOI: 10.1186/s12888-024-05619-0.Peer-Reviewed Original ResearchConceptsSmoking menthol cigarettesE-cigarettesCigarette useReduce tobacco-related health disparitiesTobacco-related health disparitiesMenthol cigarettesRates of menthol cigarette useTobacco use statusMenthol cigarette useRandomized controlled trialsPublic health problemHealth disparitiesTobacco policiesFlavored e-cigarettesSmoke-freeMenthol flavorsMenthol policiesBlack adultsQuit smokingNon-Black participantsSmoking behaviorFollow-up visitHealth problemsSecondary outcomesE-cigarette products
2023
Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs
Zakiniaeiz Y, Peltier M, Mineur Y, Gueorguieva R, Picciotto M, Petrakis I, Cosgrove K, McKee S. Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs. Journal Of Women's Health 2023, 32: 852-857. PMID: 37585509, PMCID: PMC10457604, DOI: 10.1089/jwh.2023.0015.Peer-Reviewed Original ResearchNaltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlaceboGambling participation among Connecticut adolescents from 2007 to 2019: Potential risk and protective factors
Stefanovics E, Gueorguieva R, Zhai Z, Potenza M. Gambling participation among Connecticut adolescents from 2007 to 2019: Potential risk and protective factors. Journal Of Behavioral Addictions 2023, 12: 490-499. PMID: 37335777, PMCID: PMC10316163, DOI: 10.1556/2006.2023.00027.Peer-Reviewed Original ResearchConceptsPrevalence of gamblingGambling participationPatterns of gamblingSocial supportSocial support programsGambling advertisementsTraumatic experiencesMedia coverageState of ConnecticutSocio-demographic characteristicsAffective concernsSubstance useConnecticut high school studentsGamblingAdolescent gamblingAnonymous self-completed questionnairePotential risk factorsParticipationSupport programsPublic health concernSelf-completed questionnaireCurrent substance useSocio-demographic dataCross-sectional surveyWarrants further studyDoes Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effectCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapyRandomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvementA Network Analysis of Cigarette Craving.
Aslan M, Sala M, Gueorguieva R, Garrison K. A Network Analysis of Cigarette Craving. Nicotine & Tobacco Research 2023, 25: 1155-1163. PMID: 36757093, PMCID: PMC10202645, DOI: 10.1093/ntr/ntad021.Peer-Reviewed Original ResearchThreshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration
MacLean RR, Eid T, Parida S, Gueorguieva R, DeVito EE, Sofuoglu M. Threshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration. Experimental And Clinical Psychopharmacology 2023, 31: 37-45. PMID: 35254839, PMCID: PMC9448824, DOI: 10.1037/pha0000556.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioDose of nicotineNicotine reinforcementSubjective effectsDiscriminative stimulus effectsHeart rate increaseDoses of nicotineSelf-administration procedureSubjective positive effectsDaily smokersBaseline cravingIntravenous nicotineOvernight abstinenceCigarette cravingDrug effectsMetabolite ratiosStimulus effectsSecondary analysisPlaceboSelf-AdministrationNicotine choiceTobacco productsNicotinePleasurable effectsYoung adultsThe first nicotine product tried is associated with current multiple nicotine product use and nicotine dependence among a nationally representative sample of U.S. youths
Simon P, Buta E, Jackson A, Camenga D, Kong G, Morean M, Bold K, Davis D, Krishnan-Sarin S, Gueorguieva R. The first nicotine product tried is associated with current multiple nicotine product use and nicotine dependence among a nationally representative sample of U.S. youths. Preventive Medicine 2023, 169: 107437. PMID: 36731754, PMCID: PMC10507373, DOI: 10.1016/j.ypmed.2023.107437.Peer-Reviewed Original ResearchConceptsNicotine product useSymptoms of dependenceNicotine dependenceMultiple product useSmokeless tobaccoNicotine productsProduct useSeparate multinomial logistic regression modelsHealth Study Waves 1Wave 1Smokeless tobacco usersHigher nicotine dependence scoresNicotine dependence scoresDemographic factorsLogistic regression modelsMultinomial logistic regression modelsMultivariable modelTobacco usersHigh riskDependence scoresSymptomsGreater likelihoodUse statusWave 4Regression modelsExamining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2022
Models for Zero-Inflated and Overdispersed Correlated Count Data: An Application to Cigarette Use
Pittman B, Buta E, Garrison K, Gueorguieva R. Models for Zero-Inflated and Overdispersed Correlated Count Data: An Application to Cigarette Use. Nicotine & Tobacco Research 2022, 25: 996-1003. PMID: 36318799, PMCID: PMC10077942, DOI: 10.1093/ntr/ntac253.Peer-Reviewed Original ResearchConceptsCorrelated count dataCount outcomesCount dataSubject-specific interpretationZero-InflatedIncorrect statistical inferenceStatistical inferenceCorrelated countsPoisson distributionOverdispersionModel assumptionsPoisson modelRandom effectsHurdle Poisson modelProper modelNegative binomial modelBinomial modelSuch dataAppropriate modelBest fitLarge varianceTobacco researchSuch outcomesModel fitTraining app